Why the study?
Does a single dose of recombinant human thrombopoietin improve platelet production in patients with sarcoma at high risk for chemotherapy-induced thrombocytopenia?
Population
12 patients with sarcoma who had high risk for severe chemotherapy-induced thrombocytopenia.
Design
Cohort
Follow-up
3 weeks
Authors
Loading...
May support evaluation for chemotherapy-induced thrombocytopenia; hypothesis-generating and should not change practice pending RCTs.
Does a single dose of recombinant human thrombopoietin improve platelet production in patients with sarcoma at high risk for chemotherapy-induced thrombocytopenia?
A single dose of recombinant human thrombopoietin safely and effectively stimulates prolonged platelet production in patients with sarcoma.
Vadhan‐Raj et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: